Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
Bioorg Med Chem
; 24(18): 4424-4433, 2016 09 15.
Article
em En
| MEDLINE
| ID: mdl-27501911
ABSTRACT
By means of structure-based bioisosterism approach, a series of novel purinylthioacetanilide derivatives were designed, synthesized and evaluated as potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Some of the tested compounds were found to be active against wild-type (WT) HIV-1(IIIB) with EC50 in the range of 0.78-4.46µM. Among them, LAD-8 displayed the most potent anti-HIV activity (EC50=0.78µM, SI=24). In addition, LBD-6 showed moderate activity against L100I mutant (EC50=5.64µM) and double mutant strain RES056 (EC50=22.24µM). Preliminary structure-activity relationships (SARs) were discussed in detail. Molecular modeling study was used to predict the optimal conformation in the NNRTI binding site, which may play a guiding role in further rational optimization.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
HIV-1
/
Inibidores da Transcriptase Reversa
/
Fármacos Anti-HIV
/
Acetanilidas
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article